Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

75%

6 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 4

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 3(3)

Phase 4(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT01701531Phase 2Withdrawn

Red Blood Cell Precursor Formulation to Determine Increased Production

Role: lead

NCT01534286Phase 4Terminated

A Randomized Double-Blind Placebo Controlled Trial to Determine the Status of Post Knee Chondroplasty Patients Administered Theramine Versus Placebo in Addition to Post Surgery Analgesics

Role: lead

NCT01944059Phase 4Terminated

Theramine® in the Prevention of Migraine Headache

Role: collaborator

NCT01846689Phase 3Unknown

An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease

Role: lead

NCT01537705Phase 2Unknown

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

Role: lead

NCT01490905Phase 4Completed

A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain

Role: lead

NCT01468038Phase 3Completed

A Double-blind Placebo Controlled Trial of Sentra PM, a Medical Food

Role: lead

NCT01468025Phase 3Completed

Effectiveness of Theramine on Chronic Back Pain

Role: lead

All 8 trials loaded